Cluster-randomized Controlled Trial of Enhanced Carbapenem-resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital
Apiradee Taweesuk, Pinyo Rattanaumpawan, Siriporn Rachakhom, et al
Clin Infect Dis ciaf523, https://doi.org/10.1093/cid/ciaf523
Published: 22 September 2025
Abstract
Background
Carbapenem-resistant Enterobacterales (CRE) colonization is a major risk factor for infection. Most Infection Prevention and Control (IPC) strategies rely on private-room isolation, but evidence of their effectiveness in resource-limited settings is scarce.
Methods
From February-October 2021, we conducted a cluster-randomized controlled trial in six general medical wards at Siriraj Hospital, enrolling adults with ≥1 CRE risk factor. Wards were randomized to standard IPC (sIC) or an enhanced CRE prevention program (eIC) comprising sIC plus monthly staff education, real-time notifications of CRE acquisition, and contact-precaution reminders. Active stool/rectal CRE surveillance was performed at enrollment and weekly. Primary outcomes were the CRE acquisition incidence and CRE acquisition-free time.
Results
A total of 363 patients were included: 174 in the intervention group (1,684 patient-days) and 189 in the control group (1,517 patient-days). The cumulative incidence of CRE acquisition was slightly lower in the intervention group (36.8% vs. 46.6%; p=0.06), with a significantly lower incidence rate per patient-day (0.038 vs. 0.058;p=0.007). In a post-hoc analysis excluding acquisitions within 24 hours, the cumulative incidence was similar between groups (25.7% vs. 33.6%; p=0.16). The probability of remaining CRE-free showed an unadjusted hazard ratio (HR) of 0.72 [95%CI:0.52–1.00;p=0.05]. After adjusting for prior antibiotic use, the adjusted HR was 0.75 [95%CI:0.54–1.05;p=0.09]. There were no differences in all-cause mortality or length of hospital stay.
Conclusions
CRE acquisition incidence was high in this setting. The enhanced CRE prevention program tended to reduce CRE acquisition and prolong CRE-free survival. Larger studies are needed to explore benefits on morbidity and mortality.
